A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients

• Main Authors: Dunbar Ivy, MD (Author), Maurice Beghetti, MD (Author), Ernesto Juaneda-Simian, MD, PhD (Author), Diane Miller, PhD (Author), Mary Ann Lukas, MD (Author), Chris Ioannou, PhD (Author), Malek Okour, PhD (Author), Jun Narita, MD (Author), Rolf M.F. Berger, MD, PhD (Author)
• Format: Book
• Published: Elsevier, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: To assess the safety and efficacy of the endothelin receptor antagonist ambrisentan in pediatric pulmonary arterial hypertension (PAH). Study design: In this open-label, phase IIb study, patients with PAH aged 8 to <18 years were randomized to low- or high-dose ambrisentan for 24 weeks...